Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Randomized, Double-blind, Placebo-controlled Exploratory Study to Assess the Antiepileptic Activity of BGG492 Given Orally as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

NCT01167335 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01167335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01167335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Randomized, Double-blind, Placebo-controlled Exploratory Study to Assess the Antiepileptic Activity of BGG492 Given Orally as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2010
Completion date
Not reported
Enrollment
0 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

partial onset seizures